ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 1646

The Mechanism of Umbilical Cord Mesenchymal Stem Cells in the Upregulation of Regulatory T Cells by TGF-β1 in Systemic Lupus Erythematosus

Lingyun Sun1, Dandan Wang2, Lin Lu2 and Xia Li2, 1the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Mesenchymal stem cells and systemic lupus erythematosus (SLE)

Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment II: Clinical Aspects/Pregnancy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown immunoregulation on various immune cells. The aim of this study is to investigate the mechanism of UC-MSCs in the upregulation of peripheral regulatory T cells in patients with systemic lupus erythematosus (SLE).

Methods: Peripheral blood mononuclear cells (PBMC) from 20 SLE patients and normal controls were co-cultured with UC-MSCs at the ratios of 1:1, 10:1 and 50:1 respectively for 72  hours, and the proportions of CD4+CD25+Foxp3+regulatory T cells were analyzed by flowcytometry. PBMC and serum from active SLE patients and normal controls were used to stimulate UC-MSCs, TGF-β1 mRNA expressions on UC-MSCs were detected by real-time PCR. Supernatant TGF-β1 levels were determined by ELISA. The TGF-β1 small interfering RNA (siRNA) was used to interfere TGF-β1 expression on UC-MSCs, then to determine its effect on the regulation of SLE Treg cells. TGF-β1 inhibitor was added in the culture system of UC-MSCs and PBMC from active SLE patients to observe its role on the upregulation of Treg cells by UC-MSCs.

Results: UC-MSCs could dose-dependently upregulate peripheral CD4+CD25+Foxp3+Treg proportion in SLE patients, which was not depended on cell-cell contact. UC-MSCs had no regulatory effect on Treg cells in normal controls. Compared with the non-stimulated group and normal PBMC stimulated group, PBMC from SLE patients significantly promoted TGF-β1 mRNA expression on UC-MSCs (relative gene expression was 1.00 ± 0.09, 1.95 ± 0.62, 4.20 ± 2.34, respectively, both P<0.05). Supernatant TGF-β1 levels were significantly elevated in the presence of SLE PBMC. Serum of SLE patients (5%) enhanced TGF-β1 mRNA expression on UC-MSCs (12.19 ± 4.49), remarkably higher than fetal bovine serum cultured group (1.33 ± 0.06, P<0.01) and normal control serum cultured group (2.53 ± 0.72, P<0.01). Additionally, TGF-β1 siRNA interfered UC-MSCs failed to upregulate Treg cells in SLE patients (SLE PBMC + TGF-β1siRNA UC-MSCs group 2.33% ± 0.99% vs. SLE PBMC group 1.80% ± 0.65%, P>0.05). Furthermore, in the presence of TCR stimulation, TGF-β1 specific inhibitor SB431542 significantly inhibited the regulatory role of UC-MSCs on Treg cells in SLE patients (SLE PBMC+UC-MSCs+SB431542 group 4.58%±2.10% vs. SLE PBMC+UC-MSCs group 7.85%±3.54%, P<0.05).

Conclusion: Immune microenvironment in SLE patients can significantly stimulate TGF-β1 expression on UC-MSCs, which plays an important role in the upregulation of Treg cells in patients. This study provides a new mechanism for the regulation of Treg cells by UC-MSCs in SLE.


Disclosure:

L. Sun,
None;

D. Wang,
None;

L. Lu,
None;

X. Li,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-mechanism-of-umbilical-cord-mesenchymal-stem-cells-in-the-upregulation-of-regulatory-t-cells-by-tgf-%ce%b21-in-systemic-lupus-erythematosus/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology